Added: 09.03.2015 8:18 | 26 views | 0 comments


On this weeks show, the death of Maxis Studios, what does this mean for The Sims and SimCity? Metal Gear Solid V has a release date with details on the Collectors Edition. Plus a roundup of #GDC2015 news, including details on two new/improved engines, Source 2 and Unreal Engine 4; as well as details on the Unreal Tournament alpha that was playable at the show. Theres a chunk of MMO news, where Dan dispels WOW rumours about the game going free to play and explains whats really going on. Would you believe theres copyright infringement on Kickstarter from a Harry Potter game? And Dan and Nik share a story about tigers and rhinos in Far Cry 4.

Added: 06.03.2015 10:10 | 2 views | 0 comments


IGN's Brendan Graeber and Jon Ryan go hunting for abominable snowmen in the Valley of the Yetis DLC for Far Cry 4.

Added: 06.03.2015 5:13 | 1 views | 0 comments


Aoife Wilson from Eurogamer: "Cryptozoologists! Tired of being limited to thinning the numbers of boring old regular animals in Far Cry 4? Good news - the game's latest DLC pack, included in its Season Pass, adds the Abominable Snowman to your hit list. It also includes a new storyline, a whole host of extra missions, and opens up a new secluded location for you to explore." Far Cry 4: Valley of the Yetis DLC launches 10th March.

Added: 04.03.2015 21:00 | 20 views | 0 comments


Another cross-generation game descended upon Japan this past week, which means it's time to play the guessing game as to which generation will have the sales champ. Far Cry 4 favored PS4, while Dragon Ball Xenoverse went in PS3's direction. According to 4Gamer, Dragon Quest Heroes falls for... 1. (PS3) Dragon Quest Heroes - 325,446
2. (PS4) *Dragon Quest Heroes - 269,303
3. (3DS) Zelda: Majora’s Mask 3D - 39,751
4. (PSV) God Eater 2 Rage Burst - 37,650
5. (3DS) Youkai Watch 2: Shinuchi - 16,443
6. (3DS) Pokemon Omega Ruby/Alpha Sapphire - 12,680
7. (PSV) Yuuki Yuuna Wa Yuusha de Aru: Jukai no Kioku - 10,622
8. (PS3) Dragon Ball Xenoverse - 8,249
9. (3DS) Super Smash Bros. for 3DS - 8,159
10. (3DS) Seven Deadly Sins: Unjust Sin - 7,631
11. (3DS) Monster Hunter 4 Ultimate - 7,595
12. (PS4) God Eater 2 Rage Burst - 7,405
13. (PSV) Diabolik Lovers Dark Fate - 7,263
14. (PSV) Parfait - 5,697
15. (PS3) Samurai Warriors 4-II - 5,008
16. (PS4) Dragon Ball Xenoverse - 4,995
17. (WIU) Super Smash Bros. for Wii U - 4,936
18. (3DS) Animal Crossing: New Leaf - 4,917
19. (WIU) Mario Kart 8 - 4,898
20. (PS4) The Order: 1886 - 4,840 * = Includes digital versions that were technically sold in 2014. A PS4 hardware bundle was released, which contained a download code for that version of Dragon Quest Heroes, but couldn't be downloaded until February.

Added: 03.03.2015 17:00 | 24 views | 0 comments

Around 9 million people in the United States are affected by Amblyopia, making it the number one cause of monocular blindness, according to representatives from Amblyotech. For the past two hundred years, one of the leading treatments for children affected with Amblyopia was to have them wear an eyepatch over their strong eye to stimulate better vision in the weaker one.

However, this form of "patching" therapy is not ideal, according to Ubisoft and Amblyotech.

“While current treatments options, such as eye patching, provide limited relief and have poor patient compliance due to discomfort and social stigmas, the Amblyotech-patented electronic therapy has been tested clinically to significantly increase the visual acuity of both children and adults who suffer from this condition without the use of an eye patch," Amblyotech CEO Joseph Koziak said. "With our agreement with Ubisoft, we are further able to provide physicians with a complete and accurate picture of treatment compliance to help them monitor patient progress throughout therapy."

For its part, Ubisoft senior producer Mathie Ferland called Dig Rush--in development at Ubisoft Montreal--a "breakthrough novel medical treatment" for Amblyopia.

Dig Rush, a basic side-scrolling game, utilizes both eyes to train the brain in an effort to improve visual acuity. This is done by utilizing different contrast levels of red and blue seen through stereoscopic glasses that the player wears. The game itself, played on a tablet, can automatically adjust to a person's specific eye condition. The game also naturally adapts later on as visual acuity improves.

Another issue with the patching treatment for Amblyopia, developers said, is that patients are prone to relapse after the therapy has ended. But all signs are positive so far for Dig Rush as an alternative. About 90 percent of patients have seen improvements during early testing, measuring better visual acuity just 4-6 weeks later after they started played the game.

Developers noted that the patching method is only successful about 25 percent of the time.

Amblyotech is now seeking FDA approval for Dig Rush and hopes to offer the game later this year. But you won't be able to head to iTunes and simply download the game. It will be available only through a physician's prescription. Amblyotech representatives said they see Dig Rush as a drug just like any other. It's the "next generation of a syringe," they said.

Tablets will come pre-loaded with Dig Rush and patients are asked to play about an hour per day for 4-6 weeks to see lasting results. Data from the game is measured in real time and sent to a doctor to ensure patients are following their prescription. After all, a drug only works if you take it in the proper dosage.

So how did Dig Rush come to be? Ferland recalled visiting a "hacking" event in Montreal and, by chance, he heard about about McGill researcher Dr. Robert Hess' attempts to treat Amblyopia with video games using Amblyotech's app. He approached Hess and Amblyotech about a potential partnership, and the companies have been working together since.

Amblyotech's early prototype for its game was quite rudimentary and not very fun to play, the company admitted. But after all, they aren't game designers. That's why the company jumped at the opportunity to work with Ubisoft on the project.

Of course, Ubisoft's work on Dig Rush doesn't mean they'll stop making Assassin's Creed or Far Cry games anytime soon. What do you make of Ubisoft's new moves? Let us know in the comments below!

Added: 03.03.2015 17:00 | 7 views | 0 comments

Around 9 million people in the United States are affected by Amblyopia, making it the number one cause of monocular blindness, according to representatives from Amblyotech. For the past two hundred years, one of the leading treatments for children affected with Amblyopia was to have them wear an eyepatch over their strong eye to stimulate better vision in the weaker one.

However, this form of "patching" therapy is not ideal, according to Ubisoft and Amblyotech.

“While current treatments options, such as eye patching, provide limited relief and have poor patient compliance due to discomfort and social stigmas, the Amblyotech-patented electronic therapy has been tested clinically to significantly increase the visual acuity of both children and adults who suffer from this condition without the use of an eye patch," Amblyotech CEO Joseph Koziak said. "With our agreement with Ubisoft, we are further able to provide physicians with a complete and accurate picture of treatment compliance to help them monitor patient progress throughout therapy."

For its part, Ubisoft senior producer Mathie Ferland called Dig Rush--in development at Ubisoft Montreal--a "breakthrough novel medical treatment" for Amblyopia.

Dig Rush, a basic side-scrolling game, utilizes both eyes to train the brain in an effort to improve visual acuity. This is done by utilizing different contrast levels of red and blue seen through stereoscopic glasses that the player wears. The game itself, played on a tablet, can automatically adjust to a person's specific eye condition. The game also naturally adapts later on as visual acuity improves.

Another issue with the patching treatment for Amblyopia, developers said, is that patients are prone to relapse after the therapy has ended. But all signs are positive so far for Dig Rush as an alternative. About 90 percent of patients have seen improvements during early testing, measuring better visual acuity just 4-6 weeks later after they started played the game.

Developers noted that the patching method is only successful about 25 percent of the time.

Amblyotech is now seeking FDA approval for Dig Rush and hopes to offer the game later this year. But you won't be able to head to iTunes and simply download the game. It will be available only through a physician's prescription. Amblyotech representatives said they see Dig Rush as a drug just like any other. It's the "next generation of a syringe," they said.

Tablets will come pre-loaded with Dig Rush and patients are asked to play about an hour per day for 4-6 weeks to see lasting results. Data from the game is measured in real time and sent to a doctor to ensure patients are following their prescription. After all, a drug only works if you take it in the proper dosage.

So how did Dig Rush come to be? Ferland recalled visiting a "hacking" event in Montreal and, by chance, he heard about about McGill researcher Dr. Robert Hess' attempts to treat Amblyopia with video games using Amblyotech's app. He approached Hess and Amblyotech about a potential partnership, and the companies have been working together since.

Amblyotech's early prototype for its game was quite rudimentary and not very fun to play, the company admitted. But after all, they aren't game designers. That's why the company jumped at the opportunity to work with Ubisoft on the project.

Of course, Ubisoft's work on Dig Rush doesn't mean they'll stop making Assassin's Creed or Far Cry games anytime soon. What do you make of Ubisoft's new moves? Let us know in the comments below!